Clinical trials: Filariasis
Lymphatic Filariases, Onchocerciasis
Prevalence of LF Infection in Districts Not Included in LF Control Activities
Lymphatic filariasis is a neglected tropical disease earmarked for elimination as a public health problem by the year 2020. Since the year 2000, the Global Program for the Elimination of LF has together with endemic countries…
- Trial name
- NCT03131401
- Testing
- Diagnosis of lymphatic filariasis, Diagnosis of lymphatic Filariasis and onchocerciasis, DEC Patch
- Where
- Ghana
- Volunteers
- 3,736 people
- Sponsor
- Noguchi Memorial Institute for Medical Research
Onchocerciasis, Ocular, Loiasis
Clinical Trial Evaluating the Safety and Efficacy of Levamisole in Loa Loa Microfilaremic Patients
This study aims at evaluating the safety and efficacy of levamisole in patients with loiasis infection.
- Trial name
- EOLoa (NCT04049630)
- Testing
- LEV 1 mg/kg, LEV 1,5 mg/kg, LEV 2,5 mg/kg
- Where
- Republic of the Congo
- Volunteers
- 255 people, healthy volunteers welcome
- Sponsor
- Programme National de Lutte contre l'Onchocercose, Republic of the Congo
Malaria, Filariasis
Medical Implications of Coinfection With Malaria and Filariasis Parasites
This study will examine the clinical, immunological and epidemiological effects of concurrent infections with P. falciparum and W. bancrofti or M.
- Trial name
- NCT00471666
- Where
- Mali
- Volunteers
- 1,039 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Lymphatic Filariasis Elimination by Mass Drug Administration, Monitoring and Evaluation of Mass Drug Administration for Lymphatic Filariasis
East New Britain Province Monitoring & Evaluation
While tremendous progress towards elimination of lymphatic filariasis (LF) has been made in the 20 years since the 1997 Fiftieth World Health Assembly, it is unlikely the goal of eliminating LF as a public health problem by 2020…
- Conditions
- Lymphatic Filariasis Elimination by Mass Drug Administration, Monitoring and Evaluation of Mass Drug Administration for Lymphatic Filariasis, Acceptability of Mass Drug Administration for Lymphatic Filariasis
- Trial name
- ENBP M&E (NCT04124250)
- Testing
- Observational
- Where
- Papua New Guinea
- Volunteers
- 12,930 people, healthy volunteers welcome
- Sponsor
- University Hospitals Cleveland Medical Center
Healthy Volunteers
First in Man Clinical Trial of Emodepside (BAY 44-4400)
This study will investigate the safety, tolerability, and pharmacokinetics of single ascending doses of emodepside (BAY 44-4400) in healthy male volunteers.
- Trial name
- NCT02661178
- Testing
- emodepside (BAY 44-4400)
- Where
- United Kingdom
- Volunteers
- 79 people, healthy volunteers welcome
- Sponsor
- Drugs for Neglected Diseases
Lymphatic Filariasis, Scabies
Better Options for Lymphatic Filariasis Treatment
The goal of this clinical trial is to learn if mass drug administration with moxidectin in combination with diethylcarbamazine, and albendazole (MoxDA) can treat lymphatic filariasis, scabies and strongyloidiasis in children and…
- Conditions
- Lymphatic Filariasis, Scabies, Strongyloidiasis
- Trial name
- BOLT (NCT07159373)
- Testing
- MoxDA - Moxidectin + Diethylcarbamzine (DEC) + Albendazole, IDA - Ivermectin + DEC + albendazole
- Where
- Fiji
- Volunteers
- 5,100 people, healthy volunteers welcome
- Sponsor
- Medicines Development for Global Health
Onchocerciasis
Safety of a Single Dose of Moxidectin Compared With Ivermectin in Individuals Living in Onchocerciasis Endemic Areas and in Individuals Living in Onchocerciasis Endemic Areas With High Levels of Lymphatic Filariasis Co-endemicity Receiving Concomitant Albendazole
The purpose of this phase 3b study is to determine the safety of a single dose of moxidectin, compared to a single dose of ivermectin, in individuals living in onchocerciasis endemic areas and in individuals living in…
- Trial name
- NCT04311671
- Testing
- Moxidectin, Ivermectin, Albendazole
- Where
- 2 sites in Côte d’Ivoire, Democratic Republic of the Congo
- Volunteers
- 12,979 people, healthy volunteers welcome
- Sponsor
- Medicines Development for Global Health
Onchocerciasis
Safety and Efficacy of Annual or Biannual Doses of Moxidectin or Ivermectin for Onchocerciasis
The primary purpose of this phase 3b study is to determine the safety and efficacy of moxidectin administration twice a year, compared to once a year, in maintaining undetectable levels in skin of O.
- Trial name
- NCT03876262
- Testing
- Moxidectin, Ivermectin
- Where
- Democratic Republic of the Congo
- Volunteers
- 323 people
- Sponsor
- Medicines Development for Global Health
Podoconiosis, Non-Filarial Elephantiasis
Promoting Consistent Shoe Use Among Children At High Risk for Podoconiosis
Background: Podoconiosis is a debilitating condition affecting one million people in Ethiopia. Podoconiosis is preventable if those at genetically high risk consistently protected their feet from exposure to silica nanoparticles…
- Trial name
- NCT01160523
- Where
- Ethiopia
- Volunteers
- 2,106 people
- Sponsor
- National Human Genome Research Institute (NHGRI)
Lymphatic Filariasis
Eval 3-Drug Therapy Diethylcarbamize, Albendazole and Ivermectin That Could Accelerate LF Elimination Outside of Africa
This study will determine if a combination of 3 drugs used to treat the infection that cause lymphatic filariasis (LF) due to Wuchereria bancrofti infection are more effective in killing or sterilizing the adult worms compared to…
- Trial name
- NCT01975441
- Testing
- Diethylcarbamazine, Albendazole, Ivermectin
- Where
- Papua New Guinea
- Volunteers
- 182 people, healthy volunteers welcome
- Sponsor
- University Hospitals Cleveland Medical Center
Lymphatic Filariasis
Moxidectin for LF, Cote d'Ivoire (DOLF)
The purpose of this study is to determine whether moxidectin (Mox) will be more effective than ivermectin (IVM) when used in single-dose combination therapies for lymphatic filariasis (LF).
- Trial name
- NCT04410406
- Testing
- Ivermectin, Diethylcarbamazine, Albendazole
- Where
- Côte d’Ivoire
- Volunteers
- 164 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Filariasis, Helminthiasis
Host Response to Infection and Treatment in Filarial Diseases
This study will evaluate and treat patients with filarial infections to explore in depth the immunology of the disease, including susceptibility to infection, disease development, and response to treatment.
- Conditions
- Filariasis, Helminthiasis, Parasitic Infection, Mansonelliasis
- Trial name
- NCT00001230
- Testing
- Diethylcarbamazine
- Where
- United States
- Volunteers
- 500 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Trachoma, Lymphatic Filariasis
Safety Study of Combined Azithromycin, Ivermectin and Albendazole for Trachoma and Lymphatic Filariasis
Trachoma and lymphatic filariasis (LF) are two 'Neglected Tropical Diseases' (NTDs), infectious diseases that affect millions of poor people in countries in the developing world.
- Trial name
- AZIVAL2 (NCT01903057)
- Testing
- azithromycin, ivermectin, albendazole
- Where
- Mozambique
- Volunteers
- healthy volunteers welcome
- Sponsor
- Emory University
Lymphatic Filariasis
Optimization of MDA With Existing Drug Regimens for LF: Monitoring Efficacy of Ongoing Treatment Programs in PNG
The standard regimen for elimination of lymphatic filariasis (LF) in PNG is annual administration of two drugs at the same time.
- Trial name
- MDA (NCT03268252)
- Where
- Papua New Guinea
- Volunteers
- 3,200 people, healthy volunteers welcome
- Sponsor
- University Hospitals Cleveland Medical Center
Loiasis
Loiasis Cross-reactive Antigenemia and Treatment-related Adverse Events
This study seeks to determine which Loa loa antigens are released into circulation when infected individuals are treated with ivermectin.
- Trial name
- NCT05085665
- Testing
- Ivermectin
- Where
- Cameroon
- Volunteers
- 41 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Onchocerciasis
Study Comparing Moxidectin And Ivermectin In Subjects With Onchocerca Volvulus Infection
This is a Phase 3 study comparing the efficacy, safety and tolerability of moxidectin and ivermectin in subjects infected with Onchocerca volvulus, which is the parasite that causes river blindness.
- Trial name
- NCT00790998
- Testing
- Moxidectin, Ivermectin
- Where
- 4 sites in Democratic Republic of the Congo, Ghana and 1 more
- Volunteers
- 1,497 people
- Sponsor
- Medicines Development for Global Health
Mansonelliasis, Pruritus
Epidemiology and Control of Mansonella Perstans Infection in Uganda
Mansonella perstans (M. perstans) infection is widespread in Uganda. Knowledge about the epidemiology of this infection, and of the morbidity it induces is poor, and no effective treatment is available.
- Conditions
- Mansonelliasis, Pruritus, Lymphoedema, Abdominal Pains
- Trial name
- NCT00215280
- Testing
- ivermectin and albendazole
- Where
- Uganda
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- DBL -Institute for Health Research and Development
Malaria,Falciparum, Neglected Tropical Diseases
Adjunctive Ivermectin Mass Drug Administration for Malaria Control
This is a cluster-randomized placebo-controlled clinical trial to evaluate the additive benefit of Ivermectin (IVM) (or Placebo) mass drug administration (MDA) to dihydroartemisinin-piperaquine (DP) MDA for malaria control in a…
- Conditions
- Malaria,Falciparum, Neglected Tropical Diseases, Strongyloidiasis, Lymphatic Filariasis
- Trial name
- MATAMAL (NCT04844905)
- Testing
- Ivermectin, Dihydroartemisinin-piperaquine
- Where
- Guinea-Bissau
- Volunteers
- 24,000 people, healthy volunteers welcome
- Sponsor
- London School of Hygiene and Tropical Medicine
Loiasis
Efficacy and Microfilaricidal Kinetics of Imatinib for the Treatment of Loa Loa
Background: Many people who live in west or central Africa are at risk for infection from a very small worm called Loa loa. This infection is acquired through the bite of a fly. Baby worms called microfilariae live in the blood.
- Trial name
- NCT02644525
- Testing
- Imatinib Mesylate
- Where
- Cameroon
- Volunteers
- 20 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Onchocerciasis
Study to Assess Adverse Events, Change in Disease Activity and How Oral ABBV-4083 Capsules When Given Alone or In Combination With Albendazole Capsules Moves in The Body of Adult Participants With Onchocerca Volvulus Infection
Onchocerciasis is a major public health problem in affected countries that causes disease-induced disability, and overall loss of economic productivity.
- Trial name
- NCT04913610
- Testing
- ABBV-4083, Albendazole
- Where
- 2 sites in Democratic Republic of the Congo
- Volunteers
- 153 people
- Sponsor
- AbbVie